Tumour-associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses

Cancer Biomarkers Defined by Autoantibody Signatures to Aberrant O-Glycopeptide Epitopes

(2010) H. H. Wandall et al.   CANCER RESEARCH

Characterization of murine MGL1 and MGL2 C-type lectins: Distinct glycan specificities and tumor binding properties

(2009) Satwinder Kaur Singh et al.   MOLECULAR IMMUNOLOGY

MGL2+ Dermal Dendritic Cells Are Sufficient to Initiate Contact Hypersensitivity In Vivo

(2009) Yosuke Kumamoto et al.   PLoS One

The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement

(2008) I. Caminschi et al.   BLOOD

CD8– dendritic cells preferentially cross-presentSaccharomyces cerevisiae antigens

(2008) Ronald Backer et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin

(2008) David Sancho et al.   JOURNAL OF CLINICAL INVESTIGATION

Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation

(2008) Sven Burgdorf et al.   NATURE IMMUNOLOGY

The amino acids involved in the distinct carbohydrate specificities between macrophage galactose-type C-type lectins 1 and 2 (CD301a and b) of mice

(2007) Sarawut Oo-puthinan et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS